Antitumor Activity of a Bispecific Chimera Targeting EGFR and Met in Gefitinib‐Resistant Non‐Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2024 at "Advanced Healthcare Materials"
DOI: 10.1002/adhm.202402884
Abstract: Non‐small cell lung cancers (NSCLC) frequently acquire resistance to tyrosine kinase inhibitors (TKI) due to epidermal growth factor receptor (EGFR) mutation or activation of the bypass pathway involving mesenchymal‐epithelial transition factor (Met). To address this… read more here.
Keywords: non small; egfr met; chimera; small cell ... See more keywords
Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2166
Abstract: Background: Among post-osimertinib (osi), chemotherapy-naïve patients (pts) treated with amivantamab (ami) and lazertinib (laz) in CHRYSALIS Cohort E, NGS of baseline ctDNA and tumor tissue revealed pts with identified EGFR/MET-based resistance (eg, EGFR C797S or… read more here.
Keywords: ctdna; egfr met; resistance; response ... See more keywords
Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2978
Abstract: Bispecific antibodies (BsAb) that target dual tumor-associated antigens have the advantages of invoking synergistic effects between two signaling pathways, increasing target tissue specificity, and reducing systemic toxicity. By combining the antibody-mediated specific targeting with potent… read more here.
Keywords: efficacy; egfr met; antibody drug; antibody ... See more keywords
Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0266017
Abstract: Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer in the United States, affecting one million people per year. Patients with aggressive disease have limited treatment options and high mortality,… read more here.
Keywords: egfr; tpl2; inhibition; resistance egfr ... See more keywords
Deoxypodophyllotoxin inhibits cell growth and induces apoptosis by blocking EGFR and MET in gefitinib-resistant non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of microbiology and biotechnology"
DOI: 10.4014/jmb.2101.01029
Abstract: Non-small cell lung cancer (NSCLC) is one of the major lung cancer types and accounts for the majority of cancer-related death worldwide. Treatment of NSCLC includes surgery, chemotherapy, and targeted therapy. Among the targeted therapies,… read more here.
Keywords: cancer; egfr met; growth; lung cancer ... See more keywords